Literature DB >> 26350264

ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.

Zheng Chen1, Albert E Teo1, Nami McCarty2.   

Abstract

PURPOSE: Patients with advanced stages of mantle cell lymphoma (MCL) have a poor prognosis after standard therapies. MCL cells in those patients often spread into tissues other than lymph nodes, such as the bone marrow. Apart from directed migration and homing, there is little understanding of the function of the CXCR4/SDF-1 signaling axis in MCL. In this report, we aim to understand mechanisms of MCL cell survival in the bone marrow. EXPERIMENTAL
DESIGN: For comprehensive analyses of MCL interactions with bone marrow stromal cells, we have generated gene knockout cells using CRISPR-CAS9 system and gene knockdown cells to reveal novel roles of the CXCR4/SDF-1 signaling.
RESULTS: CXCR4 silencing in MCL cells led to a significant reduction in proliferation, cell adhesion to bone marrow stromal cells, and colony formation in PHA-LCM methylcellulose medium, which were reversed upon the addition of SDF-1-neutralizing antibodies. In addition, tracking MCL cell engraftment in vivo revealed that quiescent MCL cells are significantly reduced in the bone marrow upon CXCR4 silencing, indicating that CXCR4/SDF-1 signaling is required for the survival and maintenance of the quiescent MCL cells. Further analysis revealed novel mechanisms of ROS-induced CXCR4/SDF-1 signaling that stimulate autophagy formation in MCL cells for their survival.
CONCLUSIONS: Our data, for the first time, revealed new roles of the CXCR/SDF-1 signaling axis on autophagy formation in MCL, which further promoted their survival within the bone marrow microenvironment. Targeting the CXCR4/SDF-1/autophagy signaling axis may contribute to an enhanced efficacy of current therapies. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26350264      PMCID: PMC4703439          DOI: 10.1158/1078-0432.CCR-15-0987

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  53 in total

1.  Progress in mantle-cell lymphoma.

Authors:  Peter Martin; Morton Coleman; John P Leonard
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

2.  The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem/progenitor cells.

Authors:  Katharina Rothe; Hanyang Lin; Kevin B L Lin; Amy Leung; Hui Mi Wang; Mehrnoush Malekesmaeili; Ryan R Brinkman; Donna L Forrest; Sharon M Gorski; Xiaoyan Jiang
Journal:  Blood       Date:  2014-04-22       Impact factor: 22.113

3.  Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4.

Authors:  A Peled; I Petit; O Kollet; M Magid; T Ponomaryov; T Byk; A Nagler; H Ben-Hur; A Many; L Shultz; O Lider; R Alon; D Zipori; T Lapidot
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

Review 4.  Proteasome inhibition in the treatment of cancer.

Authors:  Paul G Richardson; Constantine Mitsiades; Teru Hideshima; Kenneth C Anderson
Journal:  Cell Cycle       Date:  2005-02-03       Impact factor: 4.534

Review 5.  The role of chemokine receptor CXCR4 in lung cancer.

Authors:  Tara Gangadhar; Suvobroto Nandi; Ravi Salgia
Journal:  Cancer Biol Ther       Date:  2010-03-18       Impact factor: 4.742

6.  Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells.

Authors:  Angela Kortesidis; Andrew Zannettino; Sandra Isenmann; Songtao Shi; Tsvee Lapidot; Stan Gronthos
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

Review 7.  Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells.

Authors:  Tsvee Lapidot; Isabelle Petit
Journal:  Exp Hematol       Date:  2002-09       Impact factor: 3.084

8.  Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content.

Authors:  Salvatore Pece; Daniela Tosoni; Stefano Confalonieri; Giovanni Mazzarol; Manuela Vecchi; Simona Ronzoni; Loris Bernard; Giuseppe Viale; Pier Giuseppe Pelicci; Pier Paolo Di Fiore
Journal:  Cell       Date:  2010-01-08       Impact factor: 41.582

9.  Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice.

Authors:  H Lovec; A Grzeschiczek; M B Kowalski; T Möröy
Journal:  EMBO J       Date:  1994-08-01       Impact factor: 11.598

10.  Hypoxia-induced MIR155 is a potent autophagy inducer by targeting multiple players in the MTOR pathway.

Authors:  Gang Wan; Weidong Xie; Zhenyan Liu; Wei Xu; Yuanzhi Lao; Nunu Huang; Kai Cui; Meijian Liao; Jie He; Yuyang Jiang; Burton B Yang; Hongxi Xu; Naihan Xu; Yaou Zhang
Journal:  Autophagy       Date:  2013-11-11       Impact factor: 16.016

View more
  24 in total

1.  TG2 and NF-κB Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated Autophagy.

Authors:  Han Zhang; Zheng Chen; Roberto N Miranda; L Jeffrey Medeiros; Nami McCarty
Journal:  Cancer Res       Date:  2016-08-03       Impact factor: 12.701

Review 2.  Development and Significance of Mouse Models in Lymphoma Research.

Authors:  Jordan N Noble; Anjali Mishra
Journal:  Curr Hematol Malig Rep       Date:  2019-04       Impact factor: 3.952

Review 3.  Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma.

Authors:  Khalil Saleh; Morgane Cheminant; David Chiron; Barbara Burroni; Vincent Ribrag; Clémentine Sarkozy
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

Review 4.  CRISPR-Cas9 technology and its application in haematological disorders.

Authors:  Han Zhang; Nami McCarty
Journal:  Br J Haematol       Date:  2016-09-13       Impact factor: 6.998

Review 5.  Targeting autophagy in lymphomas: a double-edged sword?

Authors:  Han Zhang
Journal:  Int J Hematol       Date:  2018-01-27       Impact factor: 2.490

6.  3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma.

Authors:  Min Feng; Jia Wang; Ming Sun; Guilan Li; BingXiang Li; Han Zhang
Journal:  Cancer Cell Int       Date:  2021-05-26       Impact factor: 5.722

7.  Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.

Authors:  Romanos Sklavenitis-Pistofidis; Marzia Capelletti; Chia-Jen Liu; Mairead Reidy; Oksana Zavidij; Daisy Huynh; Patrick Henrick; Alexandra Savell; Kaitlen Reyes; Bradley Rivotto; Mark Bustoros; Adriana Perilla-Glen; Lorenzo Trippa; Jorge J Castillo; Steven P Treon; Irene M Ghobrial
Journal:  Blood       Date:  2018-10-26       Impact factor: 25.476

Review 8.  The hypoxia signalling pathway in haematological malignancies.

Authors:  Marta Irigoyen; Juan Carlos García-Ruiz; Edurne Berra
Journal:  Oncotarget       Date:  2017-05-30

9.  CXCR4 blockade sensitizes osteosarcoma to doxorubicin by inducing autophagic cell death via PI3K‑Akt‑mTOR pathway inhibition.

Authors:  Yu-Xin Liao; Ji-Yang Lv; Zi-Fei Zhou; Tian-Yang Xu; Dong Yang; Qiu-Ming Gao; Lin Fan; Guo-Dong Li; Hai-Yang Yu; Kai-Yuan Liu
Journal:  Int J Oncol       Date:  2021-06-03       Impact factor: 5.650

10.  Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment.

Authors:  Han Zhang; Zheng Chen; Sattva S Neelapu; Jorge Romaguera; Nami McCarty
Journal:  Oncotarget       Date:  2016-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.